Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

CSN5 Promotes Hepatocellular Carcinoma Progression by SCARA5 Inhibition Through Suppressing β-Catenin Ubiquitination.

Liu H, Hu J, Pan H, Luo D, Huang M, Xu W.

Dig Dis Sci. 2018 Jan;63(1):155-165. doi: 10.1007/s10620-017-4855-9. Epub 2017 Nov 30.

PMID:
29189991
2.

Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.

Guo H, Jing L, Cheng Y, Atsaves V, Lv Y, Wu T, Su R, Zhang Y, Zhang R, Liu W, Rassidakis GZ, Wei Y, Nan K, Claret FX.

Hepatology. 2016 Mar;63(3):898-913. doi: 10.1002/hep.28372. Epub 2016 Jan 14.

PMID:
26606000
3.

Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response.

Lee YH, Judge AD, Seo D, Kitade M, Gómez-Quiroz LE, Ishikawa T, Andersen JB, Kim BK, Marquardt JU, Raggi C, Avital I, Conner EA, MacLachlan I, Factor VM, Thorgeirsson SS.

Oncogene. 2011 Oct 6;30(40):4175-84. doi: 10.1038/onc.2011.126. Epub 2011 Apr 18.

4.

Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo.

Hsu MC, Huang CC, Chang HC, Hu TH, Hung WC.

Clin Cancer Res. 2008 Jul 1;14(13):4045-52. doi: 10.1158/1078-0432.CCR-07-5040.

Supplemental Content

Loading ...
Support Center